| Serotype | S. p isolates in PCV7 group (% of participants) n = 1475 | S. p isolates in Hib group (% of participants) n = 1475 | Percentage reduction between PCV7 and Hib groups(95% CI) | c2 | P |
| 4 | 1 (0.1) | 1 (0.1) | 0 (−1,497.2, 93.7) | 0.00 | 1.000 |
| 6B | 27 (1.8) | 35 (2.4) | 22.8 (−26.8, 53.1) | 0.25 | 0.617 |
| 9V | 1 (0.1) | 3 (0.2) | 65.0 (−220.1, 96.5) | 0.25 | 0.617 |
| 14 | 16 (1.1) | 29 (2.0) | 45.2 (−1.1, 69.9) | 3.81 | 0.051 |
| 18C | 0 (0.0) | 0 (0.0) | 0 | / | / |
| 19F | 44 (3.0) | 55 (3.8) | 20.0 (−18.1, 45.8) | 1.27 | 0.261 |
| 23F | 24 (1.7) | 18 (1.2) | −33.3 (−144.6, 27.3) | 0.87 | 0.351 |
| Total VT | 113 (7.7) | 141 (9.6) | 19.9 (−1.5, 36.8) | 3.38 | 0.066 |
| 6A | 26 (1.76) | 32 (2.17) | 18.9 (−35.6, 51.3) | 0.63 | 0.426 |
| Total VT plus 6A | 139 (9.4) | 173 (11.7) | 19.7 (0.8, 35.0) | 4.14 | 0.042 |